EA201890075A1 - Инъецируемые фармацевтические композиции лефамулина - Google Patents

Инъецируемые фармацевтические композиции лефамулина

Info

Publication number
EA201890075A1
EA201890075A1 EA201890075A EA201890075A EA201890075A1 EA 201890075 A1 EA201890075 A1 EA 201890075A1 EA 201890075 A EA201890075 A EA 201890075A EA 201890075 A EA201890075 A EA 201890075A EA 201890075 A1 EA201890075 A1 EA 201890075A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lefamulin
injectable pharmaceutical
pharmaceutical compositions
value
composition
Prior art date
Application number
EA201890075A
Other languages
English (en)
Other versions
EA033988B1 (ru
Inventor
Матиас Ференцик
Вернер Хайльмайер
Петер Хинсманн
Вольфганг Виха
Original Assignee
Набрива Терапьютикс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Набрива Терапьютикс Гмбх filed Critical Набрива Терапьютикс Гмбх
Publication of EA201890075A1 publication Critical patent/EA201890075A1/ru
Publication of EA033988B1 publication Critical patent/EA033988B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к инъецируемой фармацевтической композиции, содержащей соединение формулы (I)причем указанная композиция забуферирована до фармацевтически приемлемого значения pH, особенно значения pH, составляющего от 2 до 6, в частности значения pH, составляющего от 3 до 5,5, предпочтительно значения pH, составляющего около 4-5, особенно предпочтительно около 5.
EA201890075A 2015-06-17 2016-06-14 Инъецируемые фармацевтические композиции лефамулина EA033988B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180871P 2015-06-17 2015-06-17
PCT/EP2016/063609 WO2016202788A1 (en) 2015-06-17 2016-06-14 Injectable pharmaceutical formulations of lefamulin

Publications (2)

Publication Number Publication Date
EA201890075A1 true EA201890075A1 (ru) 2018-05-31
EA033988B1 EA033988B1 (ru) 2019-12-17

Family

ID=56131530

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890075A EA033988B1 (ru) 2015-06-17 2016-06-14 Инъецируемые фармацевтические композиции лефамулина

Country Status (27)

Country Link
US (1) US20180360966A1 (ru)
EP (1) EP3310331B1 (ru)
JP (1) JP6818019B2 (ru)
KR (1) KR102656841B1 (ru)
CN (1) CN107810000B (ru)
AU (1) AU2016278774C1 (ru)
BR (1) BR112017026904B1 (ru)
CA (1) CA2989372C (ru)
CY (1) CY1123722T1 (ru)
DK (1) DK3310331T3 (ru)
EA (1) EA033988B1 (ru)
ES (1) ES2843723T3 (ru)
HK (1) HK1252534A1 (ru)
HR (1) HRP20210010T1 (ru)
HU (1) HUE053024T2 (ru)
IL (1) IL256115A (ru)
LT (1) LT3310331T (ru)
MX (1) MX2017015812A (ru)
PH (1) PH12017502319A1 (ru)
PL (1) PL3310331T3 (ru)
PT (1) PT3310331T (ru)
RS (1) RS61327B1 (ru)
SI (1) SI3310331T1 (ru)
TW (1) TWI718158B (ru)
UA (1) UA121240C2 (ru)
WO (1) WO2016202788A1 (ru)
ZA (1) ZA201707998B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230174509A1 (en) * 2020-04-17 2023-06-08 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins
WO2021209173A1 (en) 2020-04-17 2021-10-21 Nabriva Therapeutics GmbH Novel therapeutic use of pleuromutilins
BR112022020007A2 (pt) 2020-04-17 2022-11-22 Nabriva Therapeutics GmbH Uso terapêutico de pleuromutilinas
WO2023004327A1 (en) * 2021-07-19 2023-01-26 Jbc Science Inc. Methods for isolating circulating nucleic acids from urine samples
WO2023152115A1 (en) 2022-02-09 2023-08-17 Nabriva Therapeutics GmbH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011063C (en) * 1989-02-28 1999-07-06 Calum B. Macfarlane Nicardipine pharmaceutical composition for parenteral administration
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
PL358666A1 (en) * 2000-04-04 2004-08-09 Smithkline Beecham Plc 2-hydroxy-mutilin carbamate derivatives for antibacterial use
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
JP5507049B2 (ja) * 2004-12-30 2014-05-28 アステックス、セラピューティックス、リミテッド 医薬品
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
WO2011002776A1 (en) * 2009-06-29 2011-01-06 Nitric Biotherapeutics, Inc. Pharmaceutical formulations for iontophoretic delivery of an immunomodulator
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103626693B (zh) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
AU2014273471B2 (en) * 2013-05-28 2019-10-03 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections

Also Published As

Publication number Publication date
PL3310331T3 (pl) 2021-04-19
KR20180030479A (ko) 2018-03-23
ZA201707998B (en) 2021-04-28
CN107810000B (zh) 2021-03-12
AU2016278774A1 (en) 2017-12-07
AU2016278774B2 (en) 2021-07-29
TWI718158B (zh) 2021-02-11
HUE053024T2 (hu) 2021-06-28
RS61327B1 (sr) 2021-02-26
MX2017015812A (es) 2018-07-06
SI3310331T1 (sl) 2021-02-26
EP3310331A1 (en) 2018-04-25
HK1252534A1 (zh) 2019-05-31
KR102656841B1 (ko) 2024-04-12
WO2016202788A1 (en) 2016-12-22
CA2989372A1 (en) 2016-12-22
DK3310331T3 (da) 2021-01-11
CA2989372C (en) 2023-10-03
PT3310331T (pt) 2021-01-19
CY1123722T1 (el) 2022-05-27
JP2018517777A (ja) 2018-07-05
EA033988B1 (ru) 2019-12-17
US20180360966A1 (en) 2018-12-20
LT3310331T (lt) 2021-01-11
PH12017502319A1 (en) 2018-06-25
TW201716056A (zh) 2017-05-16
BR112017026904B1 (pt) 2023-10-10
JP6818019B2 (ja) 2021-01-20
CN107810000A (zh) 2018-03-16
AU2016278774C1 (en) 2021-11-18
BR112017026904A2 (pt) 2018-08-14
IL256115A (en) 2018-02-28
ES2843723T3 (es) 2021-07-20
EP3310331B1 (en) 2020-10-14
HRP20210010T1 (hr) 2021-03-05
UA121240C2 (uk) 2020-04-27

Similar Documents

Publication Publication Date Title
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
TN2016000081A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
UY35300A (es) Formulación de combinación de dos compuestos antivirales
UA118666C2 (uk) Похідні піразолу
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
EA201500931A1 (ru) Производные пиридин-4-ила
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
PH12018500378A1 (en) Novel annelated phenoxyacetamides
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.